NCT05828459 - First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions

Hematological MalignancySolid Tumor

Interventions

DRUG

OT-A201

OT-A201 IV infusion qw or q2w

DRUG

IMids

Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle

DRUG

Bevacizumab

Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w

DRUG

Paclitaxel

Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w

DRUG

TBD Compound

Combination regimen for hematological malignancy

Trial Locations (4)

Unknown

RECRUITING

ICM - Montpellier, Montpellier

RECRUITING

Saint-Eloi Hospital - Montpellier (CHU), Montpellier

RECRUITING

Saint-Joseph Hospital - Paris, Paris

RECRUITING

Centre Eugène Marquis, Rennes